United Therapeutics (UTHR) Tops Q3 EPS by 120c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cowen Remains Bullish on United Therapeutics (UTHR) as Orenitram Continues to Grow
October 27, 2015 4:01 PM EDTCowen reiterated an Outperform rating and $185.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings results. All pulmonary hypertension products beat expectations, driving revenue and EPS above consensus.
Analyst Phil Nadeau commented, "UTHR reported strong Q3 results this morning. All pulmonary... More
Leerink Partners Reiterates Market Perform Following United Therapeutics (UTHR) 3Q beat
October 27, 2015 1:44 PM EDTLeerink Partners reiterated a Market Perform rating and $166.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings report. UTHR reported 3Q revenues and non-GAAP EPS of $386M and $3.55 that beat Street estimates of $362M and $3.22. Management reported that sales... More
